DRKS00024356已完成未知
Cross over study to assess the effect of AM-301 on allergic symptoms during allergen challenge in the Fraunhofer Allergen Challenge Chamber (ACC) in comparison to hydroxypropylmethylcellulose powder - AM-301-CL-20-02
Altamira Medica AG0 个研究点目标入组 36 人开始时间: 2021年2月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Main inclusion criteria:
- •- Women and men aged 18-65 years. Women may be included only if they are not pregnant and, in addition, are either not of childbearing potential or are using a safe method of contraception
- •- BMI between 18 and 32 kg/m2
- •- History of seasonal allergic rhinitis to grass pollen
- •- Positive skin prick test for Dactylis glomerata (alternatively sweetgrass mixture, including D. glomerata) at screening or within 12 months prior to screening visit
- •- Normal lung function (FEV1 = 80 % pred. and FEV1/FVC = 70%) at screening
- •- Adequate level of rhinitis symptoms in a grass pollen challenge, defined as a TNSS of at least 6 (out of 12) at two times within the 4-hour screening grass pollen challenge
排除标准
- •- Any clinically relevant abnormal findings in physical examination, clinical chemistry, hematology, urinanalysis, vital signs, lung function or ECG at screening visit , which, in the opinion of the investigator, may either put the subject at risk because of participation in the study or may influence the results of the study, or the subject’s ability to participate in the study
- •- Past or present concomitant medical conditions, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis).
- •- Allergen specific Immunotherapy (SIT) within 2 years prior to the study
- •- Any upper respiratory tract infection (including rhinitis and sinusitis) in the last 14 days before entering the study
- •- Asthma requiring more than inhaled short-acting beta-2 agonists (Step 2 or more severe asthma consistent with steps defined in Global Initiative for Asthma, Global Strategy for Asthma Management and Prevention, 2019).
- •- History of an acute infection four weeks prior to the informed consent visit
- •- Subjects with severe septum deviation or other structural nasal abnormalities that prevent the intranasal administration of a medical device
- •- Subject has a positive result for SARS-CoV-2 PCR test at screening and before any clinical investigation related allergen challenge
- •- Subject has clinical signs and symptoms consistent with COVID-19 infection, e.g., fever, dry cough, dyspnea, sore throat, fatigue, muscle or body aches and gastrointestinal symptoms or confirmed infection by appropriate SARS-CoV-2 PCR test within the 4 weeks prior to visit 1.
研究者
相似试验
已完成
不适用
The clinical study to assess the effect of the amount of carbohydrate intake and meals differing in glycemic index (GI) in patients treated with a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitorJPRN-UMIN000017838Kansai Electric Power Hospital24
尚未招募
3 期
Pain relieving effect of Ayurvedic drugs Amritbhallataka and Navjeevan Rasa in sciatica patientsCTRI/2024/05/066880Ch.Brahm Prakash Ayurved Charak Sansthan
尚未招募
3 期
Clinical study of Indian gooseberry seed powder (Emblica officinalis)in the management of leucorrhoeaCTRI/2023/09/057191Farida Parbin
已完成
3 期
ANZ 9311. Phase III trial to compare the effect of a short high dose intensive course of chemotherapy with filgrastim support versus a conventional standard dose course of chemotherapy in patients with advanced breast cancer.Advanced Breast CancerCancer - BreastACTRN12605000478617Australia and New Zealand Breast Cancer Trials Group Ltd225
已完成
3 期
ANZ 8811: A Phase III study to compare the effect of Zoladex depot (ICI 118,630) with Nolvadex plus Zoladex depot in pre- and peri-menopausal patients with advanced breast cancer.Advanced breast cancerCancer - BreastACTRN12606000499583Australian New Zealand Breast Cancer Trials Group (ANZ BCTG)180